- Home
- KAVL vs QNTM Comparison
KAVL vs QNTM Comparison
Compare KAVL & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- QNTM
- Stock Information
- Founded
- KAVL 1998
- QNTM 1998
- Country
- KAVL United States
- QNTM Canada
- Employees
- KAVL N/A
- QNTM N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- QNTM
- Sector
- KAVL Health Care
- QNTM
- Exchange
- KAVL Nasdaq
- QNTM NYSE
- Market Cap
- KAVL 8.9M
- QNTM 9.1M
- IPO Year
- KAVL N/A
- QNTM N/A
- Fundamental
- Price
- KAVL $1.18
- QNTM $3.48
- Analyst Decision
- KAVL
- QNTM
- Analyst Count
- KAVL 0
- QNTM 0
- Target Price
- KAVL N/A
- QNTM N/A
- AVG Volume (30 Days)
- KAVL 1.1M
- QNTM 167.1K
- Earning Date
- KAVL 02-13-2025
- QNTM 11-12-2024
- Dividend Yield
- KAVL N/A
- QNTM N/A
- EPS Growth
- KAVL N/A
- QNTM N/A
- EPS
- KAVL N/A
- QNTM N/A
- Revenue
- KAVL $10,108,906.00
- QNTM N/A
- Revenue This Year
- KAVL $652.90
- QNTM N/A
- Revenue Next Year
- KAVL N/A
- QNTM N/A
- P/E Ratio
- KAVL N/A
- QNTM N/A
- Revenue Growth
- KAVL N/A
- QNTM N/A
- 52 Week Low
- KAVL $0.58
- QNTM $2.70
- 52 Week High
- KAVL $9.69
- QNTM $70.85
- Technical
- Relative Strength Index (RSI)
- KAVL 60.50
- QNTM 43.29
- Support Level
- KAVL $0.95
- QNTM $3.15
- Resistance Level
- KAVL $1.22
- QNTM $3.55
- Average True Range (ATR)
- KAVL 0.20
- QNTM 0.36
- MACD
- KAVL 0.02
- QNTM 0.02
- Stochastic Oscillator
- KAVL 51.76
- QNTM 27.05
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.